ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
(a), (d), (e) and (f) Not applicable.
(b) The disclosure provided under Item 5.02(c) below is incorporated herein by
reference.
(c) On October 8, 2009, OXiGENE, Inc. ("OXiGENE" or the "Company") announced
that John A. Kollins has resigned from his positions as the Company's Chief
Executive Officer and member of the Board of Directors and that Dr. Peter J.
Langecker, who has served as the Company's Executive Vice President and Chief
Development Officer since June 2009, has been appointed as the Company's Interim
Chief Executive Officer pending a search for a permanent replacement for
Mr. Kollins.
Peter J. Langecker, M.D., Ph.D., 58, served as Chief Medical Officer of DURECT
Corporation from May 2006 until June 2009. Prior to joining DURECT,
Dr. Langecker served as Chief Medical Officer and Vice President of Clinical
Affairs at Intarcia Therapeutics, Inc. from October 1999 to April 2006. Prior to
that, Dr. Langecker was Vice President of Clinical Affairs at Sugen, Inc. from
1997 to 1999, Vice President, Clinical Research at Coulter Pharmaceuticals from
1995 to 1997 and Director of Clinical Research, Oncology, at Schering-Plough
from 1992 to 1995. Previously, Dr. Langecker worked as a Project
Physician-Central Medical Advisor, Oncology at Ciba-Geigy (now Novartis) in
Basel, Switzerland. He received his M.D. degree and his doctorate in medical
sciences from the Ludwig-Maximilians University in Munich.
The Company intends to enter into a separation agreement with Mr. Kollins in
connection with his departure. The terms of such agreement will be described in
an amendment to this Form 8-K following execution of the agreement.
Add
OXGN to Portfolio
Set Alert
Email to a
Friend